A RANDOMIZED PILOT STUDY OF SYSTEMIC IMMUNOSUPPRESSION IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH CHOROIDAL NEOVASCULARIZATION
- 1 November 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Retina
- Vol. 30 (10), 1579-1587
- https://doi.org/10.1097/iae.0b013e3181e7978e
Abstract
Background: Age-related macular degeneration remains the leading cause of irreversible blindness in the United States and the developed world. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications have become standard of care for the treatment of the wet form of the disease. Recent reports have demonstrated an association with various immune factors. We aimed to investigate the effect of immunosuppressive therapy in the clinical course of the wet form of the disease. We compared anti-VEGF therapy plus one of three systemic immunosuppressive therapies versus anti-VEGF therapy alone for recurrent choroidal neovascularization associated with age-related macular degeneration. Methods: This was a pilot, Phase I/II, prospective, randomized, unmasked, single-center trial. Patients with subretinal exudation secondary to recurrent choroidal neovascularization associated with age-related macular degeneration were included in the study. Patients were randomized to 1 of 3 systemic arms immunosuppressive agents (daclizumab, rapamycin, or infliximab) for 6 months plus intraocular anti-VEGF therapy if indicated, compared with a group who received only anti-VEGF therapy if indicated. Results: The number of anti-VEGF injections per group, visual acuity, retinal thickness, and safety measures were assessed in all groups. Thirteen patients were randomized; comparing anti-VEGF injections before and during the study, a decrease in the number of injections from 0.73 injections per month to 0.42 for daclizumab and from 0.67 to 0.34 for sirolimus was seen, while no apparent decrease was seen for either infliximab or observation. Visual acuities were maintained in all groups. Conclusion: These preliminary data suggest that some immunosuppressive agents given systemically can alter the clinical course of the wet form of the disease and support the notion that more definitive clinical trials of immune mediation of age-related macular degeneration are indicated.Keywords
This publication has 30 references indexed in Scilit:
- Assessing Susceptibility to Age-related Macular Degeneration with Proteomic and Genomic BiomarkersMolecular & Cellular Proteomics, 2009
- Molecular pathology of age-related macular degenerationProgress in Retinal and Eye Research, 2008
- Interleukin-8 promoter polymorphism -251A/T is a risk factor for age-related macular degenerationBritish Journal of Ophthalmology, 2008
- Oxidative damage–induced inflammation initiates age-related macular degenerationNature Medicine, 2008
- Age-related Macular Degeneration and the Immune Response: Implications for TherapyAmerican Journal of Ophthalmology, 2007
- A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degenerationProceedings of the National Academy of Sciences, 2007
- DaclizumabExpert Opinion on Biological Therapy, 2007
- The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin)Acta Ophthalmologica Scandinavica, 2007
- Regression of neovascular age-related macular degeneration following infliximab therapyAmerican Journal of Ophthalmology, 2005
- Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationJournal of Autoimmunity, 2003